Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
Harbour BioMed (HKG: 2142) announced it has exercised warrants to acquire additional common stock in Spruce...
Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
Duality Biologics (HKG: 9606) announced that its ADAM9‑targeting ADC candidate DB‑1317 has received Investigational New...
Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
Biogen Inc. (NASDAQ: BIIB) announced that the European Commission (EC) has granted marketing authorization for a...
InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
InventisBio Co., Limited (SHA: 688382) this week filed for an initial public offering (IPO) to...
Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc. (NYSE: PEN) announced a definitive agreement for Boston Scientific...
Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance
Gan & Lee Pharmaceuticals (SHA: 603087) announced that its insulin glargine injection and pre‑filled insulin...
Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China’s National Medical Products Administration (NMPA)...
J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions
Johnson & Johnson MedTech announced a strategic partnership with CED Medical, building on their 2023...
Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors
Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649,...
Vitalgen’s VGN‑R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease
Shanghai Vitalgen BioPharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent
Cardiac Biotech Solutions, Inc. (OTCMKTS: CBSC) announced that its China partner Shenzhen Ebulent has commenced...
Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
Bio‑Thera Solutions Inc. (SHA: 688177) announced a licensing agreement granting Gedeon Richter Plc. commercialization rights...
Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced a private placement to raise RMB 185 million (USD 26.5 million),...
Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
Huadong Medicine Co., Ltd (SHE: 000963) announced that the U.S. Food and Drug Administration (FDA) has...
Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted...
Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Fresenius Kabi and TQ Therapeutics announced a strategic‑development agreement granting Fresenius Kabi exclusive rights to...
BMS’s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase III Study
Bristol‑Myers Squibb (BMS, NYSE: BMY) announced positive topline results from the Phase 3 SCOUT‑HCM study evaluating mavacamten...
WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development
WuXi Biologics (HKG: 2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) global exclusive...
ABM Therapeutics Licenses MEK1/2 Inhibitor ABM‑168 to Mosaica Medicines for Global Development
ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM‑168, an...
WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA, announced its...